Climb Bio reports Phase I results for CLYM116 in IgA nephropathy

Climb Bio has reported positive initial findings from its ongoing Phase I trial of CLYM116, an APRIL monoclonal antibody to treat IgAN. The data indicate CLYM116 showed a favourable safety profile, with no serious adverse events or dose-limiting toxicities. Climb Bio is conducting the Phase II NAVIGATE-2 study of CLYM116. Credit: Stock-Asso / Shutterstock.com. Climb Bio has reported positive initial findings from its ongoing Phase I trial of CLYM116, an anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody being tested in healthy volunteers as a potential treatment for IgA nephropathy (IgAN). The double-blind, randomised, single-ascending-dose, placebo-controlled and multiple-ascending-dose study included 46 participants…

Source: Clinical Trials Arena